QuickFire Challenge fuels medical innovation
The Victorian Government in collaboration with Johnson & Johnson Innovation JLABS today announced the Victorian QuickFire Challenge, a competition giving healthcare entrepreneurs the chance to transform their ground-breaking research into the products that will advance the well-being of people around…
Victorian Health Minister officially opens Johnson & Johnson Innovation Partnering Office at Monash University
The new Johnson & Johnson Innovation Partnering Office at Monash (JJIPO@MONASH) was officially opened today by the Victorian Health Minister, Jill Hennessy at Monash University in Clayton. The office will serve as Johnson & Johnson Innovation’s local base…
MTPConnect reports strong growth in Australia’s Medtech, Biotech and Pharmaceutical sector
MTPConnect – the Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – has released new sector metrics that show jobs supported by the MTP sector increased by 10% to 62,000 from 2015 to 2016, and that manufacturing…
Korean vitamin manufacturer boosts Australia’s pharma job sector
Korean nutritional supplement producer Nutribiotech has chosen Australia as the location for its newest global manufacturing facility, creating 150 new full-time jobs over the next three years. Nutribiotech makes vitamins, minerals and nutritional supplements for several major Australian…
Australia’s clean, green & healthy image underpins surging Chinese investment in Australian healthcare
Doug Ferguson, KPMG’s National Managing Partner Asia & International Markets, discusses the latest trends from KPMG’s Demystifying Chinese Investment in Australian Healthcare report. Chinese investment in Australian healthcare companies has surged over the past three years. AUD5.5 billion has flowed…
Australia 2030: Prosperity through Innovation – Innovation and Science Australia’s strategic plan for Australia’s innovation future release
Innovation and Science Australia (ISA) has challenged Australians, and their governments, to be bolder in using innovation to unlock economic and social opportunity for the future. The call came as ISA Chair, Mr Bill Ferris AC, launched Australia…
2017 – A Big Year for Biotech!
Our vision for Victoria is to lead the world in health innovation. Discovering, developing and manufacturing the health technologies that change the world. New drugs, devices, diagnostics, vaccines, therapies and digital products – Victoria is the best place to…
Major $640 million investment in Australia’s world-leading medical research
The Turnbull Government will invest $640 million to support Australia’s world-leading health and medical researchers as they continue their work in the laboratory, clinic and the community to find the next major medical breakthrough. Cancer research continues to…
$33 million for CRC Projects to tackle diverse industry problems
http://minister.industry.gov.au/ministers/laundy/media-releases/33-million-crc-projects-tackle-diverse-industry-problems?mc_cid=da234fdd4a&mc_eid=1eb046c0f3 Better barramundi breeding, disease resistant bananas, a portable brain scanner for early stroke detection and a process to turn waste plastics into spectacle frames are amongst 15 highly diverse industry-led projects to receive a $33 million investment…
$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT
• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…
Phosphagenics Signs a Multinational License for TPM® in Personal Care Products
Phosphagenics Signs a Multinational License for TPM® in Personal Care Products 4 December 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the signing of a non-exclusive license agreement with Rodan…
Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…
